Olczyk Paweł, Koprowski Robert, Komosinska-Vassev Katarzyna, Jura-Półtorak Agnieszka, Winsz-Szczotka Katarzyna, Kuźnik-Trocha Kornelia, Mencner Łukasz, Telega Alicja, Ivanova Diana, Olczyk Krystyna
Department of Community Pharmacy, School of Pharmacy and Division of Laboratory Medicine in Sosnowiec, Medical University of Silesia, 41-200 Sosnowiec, Poland.
Department of Biomedical Computer Systems, Faculty of Computer Science and Materials Science, Institute of Computer Science, University of Silesia, 41-200 Sosnowiec, Poland.
Molecules. 2017 Jul 30;22(8):1274. doi: 10.3390/molecules22081274.
The aim of the present study is to quantitatively assess the expression of selected regulatory molecules, such as leptin, leptin receptor, and adiponectin in the blood of obese patients with type 2 diabetes both before treatment and after six months of pharmacological therapy with the long-lasting insulin analogue, insulin detemir. A significant decrease in the analysed regulatory molecules, i.e., leptin receptor and adiponectin, was found in blood plasma of the patients with untreated type 2 diabetes. These changes were accompanied by an increase in plasma leptin concentrations. Insulin treatment resulted in the normalization of plasma leptin receptor and adiponectin concentrations. The circulating leptin level did not change following anti-diabetic therapy with insulin detemir. Gender was a significant factor modifying the circulating level of all the analysed regulatory active compounds. Bioinformatic analysis was performed using Matlab with the Signal Processing Toolbox. The conducted discriminant analysis revealed that the leptin receptor, Δw(19), and adiponectin, Δw(21), were the parameters undergoing the most significant quantitative changes during the six-month therapy with insulin detemir. The conducted examinations indicated the contribution of adipocytokines-the biologically-active mediators of systemic metabolism, such as leptin and adiponectin in the pathomechanism of disorders being the basis for obesity which leads to development of insulin resistance, which, in turn, results in the occurrence of type 2 diabetes.
本研究的目的是定量评估2型糖尿病肥胖患者在治疗前以及使用长效胰岛素类似物地特胰岛素进行六个月药物治疗后的血液中所选调节分子的表达，这些调节分子包括瘦素、瘦素受体和脂联素。在未经治疗的2型糖尿病患者的血浆中，发现所分析的调节分子，即瘦素受体和脂联素显著减少。这些变化伴随着血浆瘦素浓度的升高。胰岛素治疗使血浆瘦素受体和脂联素浓度恢复正常。使用地特胰岛素进行抗糖尿病治疗后，循环瘦素水平未发生变化。性别是影响所有所分析的调节活性化合物循环水平的一个重要因素。使用Matlab和信号处理工具箱进行了生物信息学分析。所进行的判别分析显示，在使用地特胰岛素进行六个月治疗期间，瘦素受体Δw(19)和脂联素Δw(21)是发生最显著定量变化的参数。所进行的检查表明，脂肪细胞因子（全身代谢的生物活性介质，如瘦素和脂联素）在作为肥胖基础的疾病发病机制中起作用，肥胖会导致胰岛素抵抗的发展，进而导致2型糖尿病的发生。
